Intellia Therapeutics (NTLA) Common Equity (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Common Equity data on file, last reported at $620.9 million in Q1 2026.

• On a quarterly basis, Common Equity fell 20.38% year-over-year to $620.9 million in Q1 2026; TTM through Mar 2026 was $620.9 million, a 20.38% decrease from a year earlier, with the FY2025 full-year figure at $671.4 million, down 23.0% from the prior year.
• Common Equity for Q1 2026 stood at $620.9 million, down from $671.4 million in the prior quarter.
• Over the last five years, Common Equity for NTLA reached as high as $1.2 billion in Q4 2022 and fell as low as $620.9 million in Q1 2026.
• Historically, Common Equity has averaged $920.9 million across 5 years, with a median of $953.8 million in 2022.
• Across the five-year window, Common Equity soared 77.96% in 2022 and declined 26.34% in 2025, its largest moves.
• Year by year, Common Equity stood at $1.2 billion in 2022, then decreased by 15.01% to $1.1 billion in 2023, then fell by 16.97% to $872.0 million in 2024, then dropped by 23.0% to $671.4 million in 2025, then retreated by 7.51% to $620.9 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $620.9 million in Q1 2026, $671.4 million in Q4 2025, and $748.4 million in Q3 2025.